Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
BMC Cancer. 2020 Sep 9;20(1):868. doi: 10.1186/s12885-020-07378-z.
The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease.
Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m, 2 days), ifosfamide (2 g/m, 5 days), and etoposide (100 mg/m, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen.
Responses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period.
This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.
软组织肉瘤的标准化疗方案是多柔比星为基础的。本回顾性研究旨在评估吡柔比星、异环磷酰胺和依托泊苷联合治疗方案对该病患者的疗效和安全性。
2008 年至 2017 年间，25 例软组织肉瘤患者接受吡柔比星（30mg/m，2 天）、异环磷酰胺（2g/m，5 天）和依托泊苷（100mg/m，3 天）每 3 周治疗一次。主要终点是总体反应，次要终点是该方案的不良反应。
根据 RECIST 标准，该方案的反应为部分缓解（n=9，36%）、稳定疾病（n=9，36%）和进展疾病（n=7，28%）。在治疗期间，频繁出现 3 级或更高级别的血液学毒性，包括白细胞减少（96%）、发热性中性粒细胞减少（68%）、贫血（68%）和血小板计数减少（48%）。在研究期间，没有报告长期不良事件。
该方案在缓解率方面与先前发表的多柔比星为基础的联合化疗方案相当。尽管没有长期的不良事件，但根据我们的结果，严重的血液学毒性应被考虑。
